Abstract: Inhibitors of glucosylceramide degradation, to pharmaceutical compositions containing same and to the use of same in the treatment of diseases of the motor units, such as amyotrophic lateral sclerosis.

Abstract: A method of filtering an ion beam to isolate ions having a targeted charge to mass ratio includes providing a quadrupole mass filter device (2), and emitting an ion beam (1?) from a source (1) towards a quadrupole mass filter device (2). An electrical field is applied between the rods (3, 3?) of each pair of opposite rods (3, 3?) of the device (2), each field being defined by combined direct and alternative potentials, calibrating each of the electrical fields in order to create at least one exact focusing point (8) at the exit (5) The method includes generating, by means of rods (3, 3?) which are segmented longitudinally, an electrical field extending between and along each pair of segmented rods (3, 3?), and calibrating the local field segments by adjusting the settings of their respective individual DC and AC potentials in order to create at least one intermediate node.

Abstract: The invention relates to the field of retinoid X receptor (RXR) signaling and a novel vitamin A pathway called Vitamin A5 pathway. Compounds which are useful to provide (R)-9-cis-13,14-dihydroretinoic acid, an endogenous RXR ligand, are claimed as well as their uses and method for preparation thereof. The compounds of the invention are useful for pharmaceutical and nutritional uses.

Abstract: Disclosed is a process for preparation of heterogeneous monodisperse mixtures of protein conjugates with a defined degree of conjugation (1-8) obtained by using a tri-functional reagent allowing affinity concentration followed by subsequent simultaneous release-functionalization.

Abstract: A process for manufacturing by moulding an optical component includes at least the following steps: a step of providing at least one mould, during which a glass profile is provided, said glass profile including a doping according to a predetermined geometry and having a refractive index profile depending on said doping and including at least an end including at least a structuring obtained by chemically etching of said doping, said structuring forming said at least one mould, and a moulding step, during which at least a moulding material suitable for forming at least an optical component is provided and arranged in said mould in order to shape said optical component.

Abstract: The present invention relates to a polymer foam, said polymer foam comprising pores forming an open-cell polymer foam, said polymer foam comprising a supramolecular gel inside pores, and said polymer foam comprising at least one enzyme. The present invention relates to a supramolecular gel; its preparation and its applications, notably in chemical synthesis and kinetic resolution, in particular of organic compounds. The present invention also relates to flow chemistry.

Abstract: A method for concealing data in an image or a video stream inside a compression chain, being implemented by a computer and including a structuring and processing phase, during which at least one image is structured into blocks including coefficients, a phase of converting and quantifying blocks so as to generate converted and quantified coefficients, with entropic coding intended to code the converted and quantified coefficients. The method includes a step of concealing data, during which bits of the data are concealed by modifying converted and quantified coefficients located in a high frequency zone of at least some of the blocks that relate to the luminance component of the video stream and that are intra-coded. This modification is performed after the quantification but before the entropic coding.

Abstract: The present invention concerns a polymer comprising repetitive units having the following formula (I) wherein R1 is H or Me; L is a linker; R2 is the side chain of an ?-amino acid being other than arginine; m is 0 or an integer comprised from 1 to 10; n is an integer comprised from 1 to 10; and X— is a counterion.

Abstract: The present invention relates to the identification of ALMS1 as the missing player involved in the regulation of the insulin-mediated glucose uptake through GLUT4 sorting vesicles, and to the down-regulation of ALMS1 by ?PKC. Accordingly, the present invention relates to a molecule capable of preventing the binding of ?PKC on ALMS1 for use for treating or preventing diabetes, in particular type 2 diabetes. In addition, the present invention relates to a method for identifying molecule capable of preventing the binding of ?PKC on ALMS1.

Abstract: The present invention provides a powerful tool to identify personalized therapeutic strategies. In particular, the invention provides methods for determining therapeutically targetable dominant signaling pathways in a cancer sample from a subject affected with a solid cancer, determining a treatment protocol for the subject, selecting a subject for a therapy, determining whether the subject is susceptible to benefit from a therapy, predicting clinical outcome of the subject, treating the subject and/or predicting the sensitivity of a solid cancer to a therapy.

Abstract: The present invention provides Histamine Receptor 2 antagonists and pharmaceutical compositions thereof for use in the treatment or prevention of liver disease, including liver fibrosis and hepato-biliary cancers. The present invention also relates to methods for identifying candidate compounds that are useful in the treatment or prevention of liver disease, including liver fibrosis and hepato-biliary cancers.

Abstract: The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of metastases. The inventors showed in vivo that lung metastasis in GPVI deficient mice are reduced compared to controls. They demonstrated that GPVI is involved in platetet interaction with tumor cells and this interaction is mediated by EMMPRIN.). Using an anti-EMMPRIN antibody, they showed that the adhesion of platelets to tumors cells is decreased. In particular, the present invention relates to a method for the prophylactic treatment of metastases in a patient suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent which inhibits the interaction between GPVI and EMMPRIN.

Abstract: The present invention relates to a biomaterial comprising: —a membrane wound patch (a), made of a nanofibrous polymeric scaffold, —a hydrogel (b) including autologous or allogenic bone marrow-derived mesenchymal stem cells, and —a bone wound patch (c) being a nanofibrous scaffold made of polymers, wherein said scaffold has a surface coated with an interrupted coating made of multilayered droplets, said multilayered droplets being droplets composed of at least one layer pair consisting of a layer of polyanions and a layer of polycations, and wherein the bone wound patch (c) further comprises a bone growth factor; wherein the hydrogel (b) is included between the membrane wound patch (a) and the bone wound patch (c).

Abstract: A rigid foam or composition allowing a rigid foam to be obtained made from polyurethane and/or polyisocyanurate. The rigid foam or composition includes polyols selected from polyester polyols and polyether polyols; the polyols include: 5 to 50% of a polyester polyol A by weight relative to the total weight of the polyols; and a polyol B selected from polyester polyols B and polyether polyols B. The polyester polyol A is of general formula Rx-Ry-Z-Ry?-Rx? in which Z is a C3 to C8 alcohol sugar chosen from glycerol, sorbitol, erythritol, xylitol, araditol, ribitol, dulcitol, mannitol and volemitol. Ry and Ry? are diesters of formula —OOC—Cn-COO— in which n is between 2 and 34, and Rx and Rx? are identical or different C2 to C12 monoalcohols.

Abstract: A device for processing a video stream related to a specific operative procedure. The device includes: a video stream reception interface, a processor, and a memory storing instructions, such that when the instructions are executed by the processor, they configure the device for: receiving, via the video stream reception interface, the video stream having a sequence of images including an image to be processed which represents at least a portion of an anatomical element, the image to be processed being formed by processing elements; determining, by a processing function, whether or not a criterion is satisfied in the image to be processed; determining a state of progress associated with the image to be processed based on whether or not the criterion is satisfied, the state of progress being representative of a state of progress of an operative step of the specific operative procedure.

Abstract: This invention pertains to protein-drug conjugates that may be used in the treatment of cancers and to pharmaceutical compositions containing the same. The protein-drug conjugate has the following formula (I), wherein: L is a cysteine-containing protein residue linked through one or more of the cysteine groups of the protein, R1 is selected from the group consisting of arylene, arylene-heteroarylene, heteroarylene-arylene and heteroarylene, n is an integer from 0 to 5, p and q are independently 0 or 1, R2, R3 and Z are spacers, u is 0 or 1 and T is a cleavable unit sensitive to hydrolases, k is 1 or 2 and D is a cytotoxic drug residue selected from dolastatin residues, which may be identical to or different from each other when k is 2, m is the mean payload-to-protein ratio (PPR) of the conjugate, which ranges from 0.1 to 16.

Abstract: The present disclosure relates to a BIN1 protein or a BIN1 nucleic acid sequence producing or encoding the same, for a use in the treatment of X-linked centronuclear myopathy. The present invention provides compositions and methods for treatment of X-linked centronuclear myopathy. The present invention relates to a method of delivering the BIN1 polypeptide to subjects with X-linked centronuclear myopathy.

Abstract: The present invention relates to a novel pharmaceutical use of bromide, i.e. the treatment of autism spectral disorder (ASD).

Abstract: The present invention concerns a polyelectrolyte coating comprising at least one polycationic layer consisting of at least one polycation consisting of n repetitive units having the formula (1) and at least one polyanionic layer consisting of hyaluronic acid. The polyelectrolyte coating has a biocidal activity and the invention thus further refers to the use of said polyelectrolyte coating for producing a device, in particular a bacteriostatic medical device, more particularly an implantable device, comprising said polyelectrolyte coating, and a method for preparing said device and a kit.

Abstract: The present invention relates to a nucleic acid coding for a human DGKk protein lacking a functional Proline Rich Region and/or a functional EPAPE repeated Region, and to its use in the treatment of fragile X syndrome in a patient in need thereof.